Biblio

Export 111 results:
[ Author(Desc)] Title Type Year
Filters: Keyword is Biomarkers  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
P. S. Aisen, Andrieu, S., Sampaio, C., Carrillo, M., Khachaturian, Z. S., Dubois, B., Feldman, H. H., Petersen, R. C., Siemers, E., Doody, R. S., Hendrix, S. B., Grundman, M., Schneider, L. S., Schindler, R. J., Salmon, E., Potter, W. Z., Thomas, R. G., Salmon, D., Donohue, M., Bednar, M. M., Touchon, J., and Vellas, B., “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
M. S. Albert, DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., Snyder, P. J., Carrillo, M. C., Thies, B., and Phelps, C. H., “The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 270-9, 2011.
C. Alexander, Zeithamova, D., Hsiung, G. - Y. R., Mackenzie, I. R., and Jacova, C., “Decreased Prefrontal Activation during Matrix Reasoning in Predementia Progranulin Mutation Carriers.”, J Alzheimers Dis, vol. 62, no. 2, pp. 583-589, 2018.
S. L. Allison, Fagan, A. M., Morris, J. C., and Head, D., “Spatial Navigation in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 1, pp. 77-90, 2016.
Á
I. Álvarez, Aguilar, M., González, J. Manuel, Ysamat, M., Lorenzo-Bosquet, C., Alonso, A., Tartari, J. Pablo, Romero, S., Diez-Fairen, M., Carcel, M., Pujalte, F., and Pastor, P., “Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.”, J Alzheimers Dis, vol. 61, no. 1, pp. 135-143, 2018.
A
D. Andriuta, Moullart, V., Schraen, S., Devendeville, A., Meyer, M. - E., and Godefroy, O., “What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?”, J Alzheimers Dis, vol. 51, no. 3, pp. 793-800, 2016.
B
L. García Barrado, Coart, E., Vanderstichele, H. M. J., and Burzykowski, T., “Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers.”, J Alzheimers Dis, vol. 49, no. 1, pp. 187-99, 2016.
J. Bennett, Burns, J., Welch, P., and Bothwell, R., “Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1179-87, 2016.
M. Berger, Cooter, M., Roesler, A. S., Chung, S., Park, J., Modliszewski, J. L., VanDusen, K. W., J Thompson, W., Moseley, A., Devinney, M. J., Smani, S., Hall, A., Cai, V., Browndyke, J. N., Lutz, M. W., and Corcoran, D. L., “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
K. Blennow and Zetterberg, H., “The Past and the Future of Alzheimer's Disease Fluid Biomarkers.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1125-1140, 2018.
C. Giuseppina Bonomi, Assogna, M., Di Donna, M. Gaia, Bernocchi, F., De Lucia, V., Nuccetelli, M., Fiorelli, D., Loizzo, S., Mercuri, N. Biagio, Koch, G., Martorana, A., and Motta, C., “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
G. Boström, Freyhult, E., Virhammar, J., Alcolea, D., Tumani, H., Otto, M., Brundin, R. - M., Kilander, L., Löwenmark, M., Giedraitis, V., Lleo, A., von Arnim, C. A. F., Kultima, K., and Ingelsson, M., “Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 81, no. 2, pp. 629-640, 2021.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
C
X. Cao, Zhu, M., He, Y., Chu, W., Du, Y., and Du, H., “Increased Serum Acylated Ghrelin Levels in Patients with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 2, pp. 545-552, 2018.
J. M. Castellano, Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., Goate, A. M., Bales, K. R., Paul, S. M., Bateman, R. J., and Holtzman, D. M., “Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.”, Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
P. Chatterjee, Doré, V., Pedrini, S., Krishnadas, N., Thota, R., Bourgeat, P., Ikonomovic, M. D., Rainey-Smith, S. R., Burnham, S. C., Fowler, C., Taddei, K., Mulligan, R., Ames, D., Masters, C. L., Fripp, J., Rowe, C. C., Martins, R. N., and Villemagne, V. L., “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
D. - W. Chen, Wang, J., Zhang, L. - L., Wang, Y. - J., and Gao, C. - Y., “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.
L. Chen, Shen, Q., Xu, S., Yu, H., Pei, S., Zhang, Y., He, X., Wang, Q. Z., and Li, D., “5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 573-585, 2022.
D
T. Daly, Henry, V., and Bourdenx, M., “From Association to Intervention: The Alzheimer's Disease-Associated Processes and Targets (ADAPT) Ontology.”, J Alzheimers Dis, vol. 94, no. s1, pp. S87-S96, 2023.
X. - L. Ding, Tuo, Q. - Z., and Lei, P., “An Introduction to Ultrasensitive Assays for Plasma Tau Detection.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1353-1362, 2021.
A. Dodich, Cerami, C., Cappa, S. F., Marcone, A., Golzi, V., Zamboni, M., Giusti, M. Cristina, and Iannaccone, S., “Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers.”, J Alzheimers Dis, vol. 61, no. 2, pp. 761-772, 2018.
J. D. Doecke, Rembach, A., Villemagne, V. L., Varghese, S., Rainey-Smith, S., Sarros, S., Evered, L. A., Fowler, C. J., Pertile, K. K., Rumble, R. L., Trounson, B., Taddei, K., Laws, S. M., S Macaulay, L., Bush, A. I., Ellis, K. A., Martins, R., Ames, D., Silbert, B., Vanderstichele, H., Masters, C. L., Darby, D. G., Li, Q. - X., and Collins, S., “Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.”, J Alzheimers Dis, vol. 61, no. 1, pp. 169-183, 2018.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
T. Dziedzic, Pera, J., Klimkowicz-Mrowiec, A., Mroczko, B., and Slowik, A., “Biochemical and Radiological Markers of Alzheimer's Disease Progression.”, J Alzheimers Dis, vol. 50, no. 3, pp. 623-44, 2016.

Pages